oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Paracetamol Aflofarm – recalled product

Paracetamol Aflofarm

HIGH 06.03.2024

It was found that a homogeneous suspension could not be obtained and sediment remained at the bottom of the bottle, which may lead to incorrect dosing of the medicine, including in children from three months of age. Potential effects: lack of efficacy or overdose, possible adverse reactions and complications.

Levosimendan Kabi – recalled product

Levosimendan Kabi

CRITICAL 04.03.2024

The product was found to be contaminated with particles visible to the naked eye in 9 of 20 tested vials of the 2.5 mg/ml concentrate for solution for infusion, which means it does not meet quality specification requirements. Potential effects: complications after intravenous administration, emboli, local reactions, lack of therapy safety.

Levosimendan Kabi – recalled product

Levosimendan Kabi

CRITICAL 04.03.2024

Testing by NIL showed that the product does not meet quality specification requirements regarding contamination with particles visible to the naked eye; in 9 of 20 tested vials such particles were found. Potential effects: complications after intravenous infusion, embolism, inflammation, local or systemic reactions.

Misintu – recalled product

Misintu

CRITICAL 12.02.2024

In the prepared solution for injection, visible insoluble particles of unknown nature and origin were detected, which may enter the patient’s bloodstream and cause unpredictable negative health effects. Potential effects: embolic complications, vascular damage, severe systemic reactions, life-threatening conditions.

Misintu – recalled product

Misintu

CRITICAL 12.02.2024

Visible to the naked eye, insoluble particles of unknown nature and origin were found in prepared solutions of the medicinal product in the form of an injection solution, which may create a real danger of these particles entering the patient's bloodstream. Potential effects: embolic complications, vascular damage, unpredictable systemic reactions.

Vblaast 10 – recalled product

Vblaast 10

CRITICAL 09.02.2024

Visible, unidentified crystals were found in the medicinal product in the form of an injection solution, creating a real danger of crystals entering the patient’s bloodstream and causing serious, unpredictable health consequences. Potential effects: thrombotic complications, vascular damage, embolism, severe systemic complications.

Reparil Gel N – recalled product

Reparil Gel N

CRITICAL 09.02.2024

Test results showed a value above the limit for aescinol content – a degradation product of the active substance – which constitutes a real and direct risk to patients’ health or life until the cause of the deviation is clarified. Potential effects: possible toxicological effects, lack of treatment safety, complications.

Vblaast 10 – recalled product

Vblaast 10

CRITICAL 09.02.2024

Visible to the naked eye crystals of unidentified origin were found in the medicinal product in the form of a solution for injection; their entry into the patient’s bloodstream may lead to unpredictable adverse health effects. Potential effects: vascular complications, organ damage, severe systemic complications.

Cytostin – recalled product

Cytostin

CRITICAL 05.02.2024

In the medicinal product in the form of a solution for injection, crystals of unidentified origin were found, creating a real danger of administering an incorrect active substance dose or of crystals entering the patient’s bloodstream. Potential effects: lack of treatment efficacy, serious vascular complications, life‑threatening events.

Cytostin – recalled product

Cytostin

CRITICAL 05.02.2024

In the medicinal product in the form of a solution for injection, visible crystals of unidentified origin were found, probably formed by crystallization of the active substance, which may result in an incorrect dose content and the crystals entering the patient’s bloodstream. Potential effects: cytostatic poisoning, lack of efficacy or thromboembolic complications.

Zodgane – recalled product

Zodgane

MEDIUM 30.01.2024

The product does not meet quality requirements due to an out-of-specification result for the particle size distribution parameter D(0.9) in the nasal spray. Potential effects: possible altered drug deposition, reduced efficacy or local adverse reactions.

Symibace – recalled product

Symibace

HIGH 25.01.2024

Given the test results indicating significant exceedances of the specification limit for the content of impurity B, the health risk to humans from keeping these medicinal product batches on the market is real and likely. Potential effects: possible poisoning, increased adverse reactions, lack of treatment safety.

Symibace – recalled product

Symibace

HIGH 25.01.2024

Taking into account test results showing a significant exceedance of the specification limit for impurity B content, the risk to human health from leaving these medicinal product batches on the market is real and probable. Potential effects: toxicity, adverse reactions, therapeutic complications.

Symibace – recalled product

Symibace

HIGH 25.01.2024

Given the test results indicating significant exceedance of the specification limit for impurity B content, the threat to human health from leaving these batches of the medicinal product on the market is real and likely. Potential effects: poisoning, adverse reactions, cardiovascular complications.

Symibace – recalled product

Symibace

HIGH 25.01.2024

Considering the test results indicating a significant exceedance of the specification limit for impurity B content, the risk to human health resulting from keeping these batches of the medicinal product on the market is real and probable. Potential effects: possible toxicity, adverse effects, treatment complications.

Corsib – recalled product

Corsib

CRITICAL 18.01.2024

Unidentified degradation impurities of the active substance pose a real and direct threat to patients; due to their unconfirmed nature, a risk to the patient’s health and life cannot be excluded. Potential effects: severe adverse reactions, complications, life‑threatening events.

Corsib – recalled product

Corsib

CRITICAL 18.01.2024

Due to the unconfirmed nature of degradative impurities of the active substance, a risk to the patient’s health and life cannot be excluded; the unidentified impurities pose a real and direct threat to patients using the product. Potential effects: poisoning, unpredictable adverse reactions, lack of efficacy in treating heart disease and hypertension.

Clotidal MAX – recalled product

Clotidal MAX

MEDIUM 15.01.2024

Negative test result for the appearance parameter – damaged, chipped tablet edges and detached fragments, probably due to too low water content in the granulate and lower hardness, which may affect dose integrity and comfort of use. Potential effects: reduced treatment efficacy or irritation.

Trazodone Neuraxpharm – recalled product

Trazodone Neuraxpharm

LOW 10.01.2024

An out-of-specification (OOS) result was recorded for the tablet hardness parameter, potentially linked to different blister foils and gas permeability, which could affect product hardness during storage. Potential effects: possible changes in active substance release, altered bioavailability and efficacy, although the investigation showed no significant impact.

Underground Super Lemon dietary supplement (lemon-pineapple flavor) – recalled product

Underground Super Lemon dietary supplement (lemon-pineapple flavor)

HIGH 29.12.2023

High content of Δ9-THC in the dietary supplement. Potential effects: poisoning, psychological disturbances and health risks.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.